Lilly rides Mounjaro, Zepbound to better
Time:2024-05-19 11:06:12 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Nelly Korda seizes 2
Next:Nelly Korda seizes 2
You may also like
- Putin: Join hands for future success of Russia
- Meghan's fruity flop? Only THREE unfamous faces out of 50 chosen jam
- New Mexico special legislative session to focus on public safety initiatives
- Video: Escaped circus elephant stops traffic in Montana
- Soto, Judge and Stanton give Yankees first teammates trio of season with double
- An NPR editor who wrote a critical essay on the company has resigned after being suspended
- Kansas' higher ed board is considering an anti
- The U.N. rights chief says eastern Congo's escalating violence is being forgotten by the world
- EU urges Israel to 'immediately' end military operation in Rafah